You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePravastatin
Accession NumberDB00175  (APRD00328)
TypeSmall Molecule
GroupsApproved
Description

Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered. It is a ring-opened dihydroxyacid with a 6’-hydroxyl group that does not require in vivo activation. Pravastatin is one of the lower potency statins; however, its increased hydrophilicity is thought to confer advantages such as minimal penetration through lipophilic membranes of peripheral cells, increased selectivity for hepatic tissues, and a reduction in side effects compared with lovastatin and simvastatin.

Structure
Thumb
Synonyms
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
Pravastatin acid
Pravastatina
Pravastatine
Pravastatinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-pravastatintablet20 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Ach-pravastatintablet10 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Ach-pravastatintablet40 mgoralAccord Healthcare IncNot applicableNot applicableCanada
Act Pravastatintablet40 mgoralActavis Pharma Company2003-12-09Not applicableCanada
Act Pravastatintablet20 mgoralActavis Pharma Company2003-12-09Not applicableCanada
Act Pravastatintablet10 mgoralActavis Pharma Company2003-12-09Not applicableCanada
Ava-pravastatintablet40 mgoralAvanstra Inc2011-10-112011-12-12Canada
Ava-pravastatintablet20 mgoralAvanstra Inc2011-10-112011-12-12Canada
Ava-pravastatintablet10 mgoralAvanstra Inc2011-10-112011-12-12Canada
Bio Pravastatintablet40 mgoralBioenhance Medicines Inc.2001-07-122003-02-27Canada
Bio Pravastatintablet20 mgoralBioenhance Medicines Inc.2001-07-122003-02-27Canada
Bio Pravastatintablet10 mgoralBioenhance Medicines Inc.2001-07-122003-02-27Canada
Bio-pravastatintablet40 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-pravastatintablet20 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-pravastatintablet10 mgoralBiomed PharmaNot applicableNot applicableCanada
Dom-pravastatintablet40 mgoralDominion Pharmacal2004-05-12Not applicableCanada
Dom-pravastatintablet20 mgoralDominion Pharmacal2004-05-12Not applicableCanada
Dom-pravastatintablet10 mgoralDominion Pharmacal2004-05-12Not applicableCanada
Ipg-pravastatintablet10 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-pravastatintablet40 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-pravastatintablet20 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-pravastatintablet40 mgoralJamp Pharma Corporation2010-04-01Not applicableCanada
Jamp-pravastatintablet20 mgoralJamp Pharma Corporation2010-04-01Not applicableCanada
Jamp-pravastatintablet10 mgoralJamp Pharma Corporation2010-04-01Not applicableCanada
Lin-pravastatintablet10 mgoralLinson Pharma Co.2000-07-132006-05-29Canada
Lin-pravastatintablet40 mgoralLinson Pharma Co.2000-07-132006-05-29Canada
Lin-pravastatintablet20 mgoralLinson Pharma Co.2000-07-132006-05-29Canada
Mar-pravastatintablet40 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-pravastatintablet20 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-pravastatintablet10 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mint-pravastatintablet20 mgoralMint Pharmaceuticals Inc2009-02-06Not applicableCanada
Mint-pravastatintablet10 mgoralMint Pharmaceuticals Inc2009-02-06Not applicableCanada
Mint-pravastatintablet40 mgoralMint Pharmaceuticals Inc2009-02-06Not applicableCanada
Mylan-pravastatintablet20 mgoralMylan Pharmaceuticals Ulc2005-04-07Not applicableCanada
Mylan-pravastatintablet10 mgoralMylan Pharmaceuticals Ulc2005-04-07Not applicableCanada
Mylan-pravastatintablet40 mgoralMylan Pharmaceuticals Ulc2005-04-07Not applicableCanada
Ntp-pravastatintablet10 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-pravastatintablet40 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-pravastatintablet20 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Nu-pravastatin Tabletstablet40 mgoralNu Pharm Inc2002-05-162012-09-04Canada
Nu-pravastatin Tabletstablet20 mgoralNu Pharm Inc2002-05-022012-09-04Canada
Nu-pravastatin Tabletstablet10 mgoralNu Pharm Inc2002-05-132012-09-04Canada
Pendo-pravastatintablet20 mgoralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
Pendo-pravastatintablet10 mgoralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
PMS-pravastatintablet40 mgoralPharmascience Inc2003-07-21Not applicableCanada
PMS-pravastatintablet20 mgoralPharmascience Inc2003-07-21Not applicableCanada
PMS-pravastatintablet10 mgoralPharmascience Inc2003-07-21Not applicableCanada
Pravacholtablet20 mg/1oralE.R. Squibb & Sons, L.L.C.2009-06-01Not applicableUs
Pravacholtablet80 mgoralBristol Myers Squibb CanadaNot applicableNot applicableCanada
Pravacholtablet80 mg/1oralE.R. Squibb & Sons, L.L.C.2009-06-01Not applicableUs
Pravacholtablet40 mg/1oralE.R. Squibb & Sons, L.L.C.2009-06-01Not applicableUs
Pravachol - Tab 10mgtablet10 mgoralBristol Myers Squibb Canada1990-12-31Not applicableCanada
Pravachol - Tab 20mgtablet20 mgoralBristol Myers Squibb Canada1990-12-31Not applicableCanada
Pravachol - Tab 40mgtablet40 mgoralBristol Myers Squibb Canada1996-08-21Not applicableCanada
Pravastatintablet40 mgoralSivem Pharmaceuticals Ulc2012-07-23Not applicableCanada
Pravastatintablet40 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Pravastatintablet20 mgoralSivem Pharmaceuticals Ulc2012-07-23Not applicableCanada
Pravastatintablet20 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Pravastatintablet40 mgoralMeliapharm Inc2004-07-222014-06-25Canada
Pravastatintablet10 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Pravastatintablet10 mgoralSivem Pharmaceuticals Ulc2012-07-23Not applicableCanada
Pravastatintablet20 mgoralMeliapharm Inc2004-07-222014-06-25Canada
Pravastatintablet40 mgoralSanis Health Inc2010-12-01Not applicableCanada
Pravastatintablet40 mgoralSorres Pharma Inc2009-02-262014-06-20Canada
Pravastatintablet10 mgoralMeliapharm Inc2004-07-222014-06-25Canada
Pravastatintablet20 mgoralSanis Health Inc2010-11-23Not applicableCanada
Pravastatintablet10 mgoralSanis Health Inc2010-11-23Not applicableCanada
Pravastatintablet20 mgoralSorres Pharma Inc2009-02-262014-06-20Canada
Pravastatintablet10 mgoralSorres Pharma Inc2009-02-262014-06-20Canada
Pravastatin Tabletstablet40 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Pravastatin Tabletstablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Pravastatin Tabletstablet10 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Pravastatin-10tablet10 mgoralPro Doc Limitee2002-12-23Not applicableCanada
Pravastatin-20tablet20 mgoralPro Doc Limitee2002-12-23Not applicableCanada
Pravastatin-40tablet40 mgoralPro Doc Limitee2002-12-23Not applicableCanada
Priva-pravastatintablet10 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-pravastatintablet40 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-pravastatintablet20 mgoralPharmapar IncNot applicableNot applicableCanada
Q-pravastatintablet40 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-pravastatintablet20 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-pravastatintablet10 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Ran-pravastatintablet40 mgoralRanbaxy Pharmaceuticals Canada Inc.2007-05-16Not applicableCanada
Ran-pravastatintablet20 mgoralRanbaxy Pharmaceuticals Canada Inc.2007-05-16Not applicableCanada
Ran-pravastatintablet10 mgoralRanbaxy Pharmaceuticals Canada Inc.2007-05-16Not applicableCanada
Ratio-pravastatintablet10 mgoralRatiopharm Inc Division Of Teva Canada Limited2003-02-032014-09-19Canada
Ratio-pravastatintablet40 mgoralRatiopharm Inc Division Of Teva Canada Limited2003-02-032014-09-19Canada
Ratio-pravastatintablet20 mgoralRatiopharm Inc Division Of Teva Canada Limited2003-02-032014-09-19Canada
Riva-pravastatintablet40 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-pravastatintablet40 mgoralLaboratoire Riva Inc2004-10-222005-06-30Canada
Riva-pravastatintablet20 mgoralLaboratoire Riva Inc2004-10-222005-06-30Canada
Riva-pravastatintablet20 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-pravastatintablet10 mgoralLaboratoire Riva Inc2004-10-222005-06-30Canada
Riva-pravastatintablet10 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-pravastatintablet40 mgoralLaboratoire Riva Inc2005-10-28Not applicableCanada
Riva-pravastatintablet20 mgoralLaboratoire Riva Inc2005-10-28Not applicableCanada
Riva-pravastatintablet10 mgoralLaboratoire Riva Inc2005-10-28Not applicableCanada
Sandoz Pravastatintablet20 mgoralSandoz Canada Incorporated2003-08-12Not applicableCanada
Sandoz Pravastatintablet40 mgoralSandoz Canada Incorporated2003-08-12Not applicableCanada
Sandoz Pravastatintablet10 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Pravastatintablet20 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Pravastatintablet10 mgoralSandoz Canada Incorporated2003-12-08Not applicableCanada
Sandoz Pravastatintablet40 mgoralSandoz Canada IncorporatedNot applicableNot applicableCanada
Teva-pravastatintablet40 mgoralTeva Canada Limited2003-01-08Not applicableCanada
Teva-pravastatintablet20 mgoralTeva Canada Limited2003-01-08Not applicableCanada
Teva-pravastatintablet10 mgoralTeva Canada Limited2003-01-08Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-pravastatintablet40 mgoralApotex Inc2001-02-27Not applicableCanada
Apo-pravastatintablet20 mgoralApotex Inc2001-02-27Not applicableCanada
Apo-pravastatintablet10 mgoralApotex Inc2001-02-27Not applicableCanada
Pravastatintablet80 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2006-10-23Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralNorthwind Pharmaceuticals, LLC2014-07-10Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralSandoz Inc2014-04-28Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralREMEDYREPACK INC.2011-06-08Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-07-22Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralAphena Pharma Solutions Tennessee, Llc2006-04-25Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralTeva Pharmaceuticals USA Inc2006-04-25Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralAv Kare, Inc.2014-06-17Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralPhysicians Total Care, Inc.2006-05-11Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-03-30Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralAidarex Pharmaceuticals LLC2010-03-30Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralInternational Laboratories, Inc.2015-05-01Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralAmerican Health Packaging2011-10-01Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralCardinal Health2012-02-10Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralbryant ranch prepack2006-10-23Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralAidarex Pharmaceuticals LLC2010-03-30Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralMc Kesson Contract Packaging2013-04-12Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralBlenheim Pharmacal, Inc.2012-02-13Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-03-30Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralSandoz Inc2014-07-28Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralCardinal Health2012-02-10Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralGolden State Medical Supply2011-07-18Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralCardinal Health2007-05-11Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralProficient Rx LP2010-03-30Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralPhysicians Total Care, Inc.2009-12-11Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralSt Marys Medical Park Pharmacy2013-08-14Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralGolden State Medical Supply2011-07-18Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralMylan Pharmaceuticals Inc.2012-10-04Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralAphena Pharma Solutions Tennessee, Inc.2011-07-18Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralAv Kare, Inc.2014-06-17Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralPhysicians Total Care, Inc.2006-05-11Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralLupin Pharmaceuticals, Inc.2008-07-24Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralMed Vantx, Inc.2006-04-25Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralUnit Dose Services2011-07-18Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralRebel Distributors Corp2006-10-23Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralPreferred Pharmaceuticals, Inc.2013-01-07Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralBlenheim Pharmacal, Inc.2014-02-19Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralClinical Solutions Wholesale2011-07-18Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralCardinal Health2007-05-11Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralProficient Rx LP2010-03-30Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralSt Marys Medical Park Pharmacy2013-08-14Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralNorthwind Pharmaceuticals, LLC2014-11-12Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralSandoz Inc2014-04-28Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralPhysicians Total Care, Inc.2007-01-25Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralLupin Pharmaceuticals, Inc.2008-07-24Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralCadila Healthcare Limited2010-03-30Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralAv Pak2016-03-15Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralRebel Distributors Corp2006-10-23Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralGlenmark Pharmaceuticals Inc., Usa2007-12-28Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralMajor Pharmaceuticals2010-07-06Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralCipla USA Inc.2006-10-23Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralClinical Solutions Wholesale2011-07-18Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralCardinal Health2008-08-01Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralDIRECT RX2015-12-28Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralApotex Corp.2011-07-18Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralREMEDYREPACK INC.2013-11-052016-04-05Us
Pravastatin Sodiumtablet40 mg/1oralMylan Institutional Inc.2007-10-03Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralSandoz Inc2014-04-28Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralMylan Pharmaceuticals Inc.2012-10-04Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralPd Rx Pharmaceuticals, Inc.2010-03-30Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralRebel Distributors Corp2007-05-11Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralCipla USA Inc.2006-10-23Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralClinical Solutions Wholesale2011-07-18Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralCardinal Health2010-07-06Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralDIRECT RX2015-12-28Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralApotex Corp.2011-07-18Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralREMEDYREPACK INC.2013-07-012016-04-05Us
Pravastatin Sodiumtablet20 mg/1oralMylan Institutional Inc.2006-05-22Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2014-04-28Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralMylan Pharmaceuticals Inc.2012-10-04Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralPd Rx Pharmaceuticals, Inc.2010-03-30Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralRebel Distributors Corp2007-05-11Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralInternational Laboratories, Inc.2013-04-26Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralLupin Pharmaceuticals, Inc.2008-07-24Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralCadila Healthcare Limited2010-03-30Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralAv Pak2016-03-15Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralRebel Distributors Corp2006-10-23Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralGlenmark Pharmaceuticals Inc., Usa2007-05-11Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralMajor Pharmaceuticals2010-07-06Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralClinical Solutions Wholesale2011-07-18Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralDr.Reddy's Laboratories Limited2009-12-31Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralREMEDYREPACK INC.2015-12-10Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralApotex Corp.2011-07-18Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralREMEDYREPACK INC.2013-07-01Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralUnit Dose Services2011-07-18Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2014-04-28Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralMylan Pharmaceuticals Inc.2012-10-04Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralPd Rx Pharmaceuticals, Inc.2009-12-31Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-07-18Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralInternational Laboratories, Inc.2009-02-09Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralLupin Pharmaceuticals, Inc.2008-07-24Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralCadila Healthcare Limited2010-03-30Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralActavis Pharma, Inc.2007-12-28Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralGlenmark Pharmaceuticals Inc., Usa2007-05-11Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralMajor Pharmaceuticals2010-07-06Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralCipla USA Inc.2006-10-23Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralCardinal Health2013-05-24Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralDr.Reddy's Laboratories Limited2009-12-31Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralREMEDYREPACK INC.2015-03-03Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralApotex Corp.2011-07-18Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralREMEDYREPACK INC.2013-05-232016-04-05Us
Pravastatin Sodiumtablet40 mg/1oralREMEDYREPACK INC.2011-11-30Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-09-29Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralTeva Pharmaceuticals USA Inc2008-09-29Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralPd Rx Pharmaceuticals, Inc.2009-12-31Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-07-18Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralInternational Laboratories, Inc.2008-03-27Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralAmerican Health Packaging2014-05-30Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralCadila Healthcare Limited2010-03-30Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralActavis Pharma, Inc.2006-10-23Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralGlenmark Pharmaceuticals Inc., Usa2007-05-11Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralMajor Pharmaceuticals2008-08-01Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralCipla USA Inc.2006-10-23Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralREMEDYREPACK INC.2015-03-03Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralGolden State Medical Supply2011-07-18Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralREMEDYREPACK INC.2013-05-232016-04-05Us
Pravastatin Sodiumtablet10 mg/1oralREMEDYREPACK INC.2011-11-17Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralTeva Pharmaceuticals USA Inc2006-04-25Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralAv Kare, Inc.2014-06-17Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-07-18Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralInternational Labs, Inc.2012-02-20Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralAmerican Health Packaging2011-10-01Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralbryant ranch prepack2010-03-30Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralActavis Pharma, Inc.2006-10-23Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-03-30Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralMajor Pharmaceuticals2008-08-01Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralREMEDYREPACK INC.2015-12-08Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralCardinal Health2013-05-24Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralDr.Reddy's Laboratories Limited2009-12-31Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralNorthwind Pharmaceuticals, LLC2014-11-12Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralREMEDYREPACK INC.2011-09-20Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-07-22Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralTeva Pharmaceuticals USA Inc2006-04-25Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralAv Kare, Inc.2014-06-17Not applicableUs
Pravastatin Sodiumtablet80 mg/1oralAidarex Pharmaceuticals LLC2010-03-30Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralInternational Laboratories, Inc.2015-05-01Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralAmerican Health Packaging2011-10-01Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralbryant ranch prepack2006-10-23Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralCobalt Laboratories Inc.2006-10-232015-12-29Us
Pravastatin Sodiumtablet40 mg/1oralBlenheim Pharmacal, Inc.2012-02-13Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-03-30Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralMajor Pharmaceuticals2008-08-01Not applicableUs
Pravastatin Sodiumtablet20 mg/1oralREMEDYREPACK INC.2014-10-03Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralCardinal Health2013-05-24Not applicableUs
Pravastatin Sodiumtablet10 mg/1oralDr.Reddy's Laboratories Limited2009-12-31Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralREMEDYREPACK INC.2014-10-03Not applicableUs
Pravastatin Sodiumtablet40 mg/1oralGolden State Medical Supply2011-07-18Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ElisorNot Available
LipostatNot Available
MevalotinNot Available
PravaselectNot Available
SelipranNot Available
Brand mixtures
NameLabellerIngredients
Pal-pravastatin-asaPaladin Labs Inc
Salts
Name/CASStructureProperties
Pravastatin Sodium
Thumb
  • InChI Key: VWBQYTRBTXKKOG-NJUCWUMRNA-M
  • Monoisotopic Mass: 446.228048149
  • Average Mass: 446.5096
DBSALT000146
Categories
UNIIKXO2KT9N0G
CAS number81093-37-0
WeightAverage: 424.5277
Monoisotopic: 424.246103506
Chemical FormulaC23H36O7
InChI KeyInChIKey=TUZYXOIXSAXUGO-PZAWKZKUSA-N
InChI
InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1
IUPAC Name
(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
SMILES
[H][C@]12[[email protected]](C[[email protected]](O)C=C1C=C[[email protected]](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as carbocyclic fatty acids. These are fatty acids containing a carbocylic ring .
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassFatty Acyls
Sub ClassFatty acids and conjugates
Direct ParentCarbocyclic fatty acids
Alternative Parents
Substituents
  • Medium-chain hydroxy acid
  • Fatty alcohol
  • Carbocyclic fatty acid
  • Medium-chain fatty acid
  • Fatty acid ester
  • Branched fatty acid
  • Beta-hydroxy acid
  • Hydroxy acid
  • Dicarboxylic acid or derivatives
  • Secondary alcohol
  • Carboxylic acid ester
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of hypercholesterolemia and to reduce the risk of cardiovascular disease.
PharmacodynamicsThe primary cause of cardiovascular (CV) disease is atherosclerotic plaque formation and sustained elevation of cholesterol in the blood increases the risk of CV disease. Pravastatin lowers hepatic production of cholesterol by competitively inhibiting HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in the cholesterol biosynthesis pathway via the mevalonic acid pathway. Decreased hepatic cholesterol levels causes increased uptake of low density lipoprotein (LDL) cholesterol and reduces cholesterol levels in the circulation. Pravastatin also inhibits hepatic synthesis if VLDL. At therapeutic doses, pravastatin lowers LDL cholesterol by 20-30%, increase high density lipoprotein (HDL) cholesterol by 3-10%, and decrease plasma triglycerides by 19-34%. HDL cholesterol is thought to confer protective effects against CV disease, whereas high LDL and triglyceride levels are associated with higher risk of disease.
Mechanism of actionPravastatin is structurally similar to the HMG, a substituent of the endogenous substrate of HMG-CoA reductase. Unlike its parent compound, mevastatin, and statins such as lovastatin and simvastatin, pravastatin does not need to be activated in vivo. Its hydrolyzed lactone ring mimics the tetrahedral intermediate produced by the reductase allowing the agent to bind with a much greater affinity than its natural substrate. The bicyclic portion of pravastatin binds to the coenzyme A portion of the active site. Pravastatin sodium produces its lipid-lowering effect in two ways. First, as a consequence of its reversible inhibition of HMG-CoA reductase activity, it effects modest reductions in intracellular pools of cholesterol. This results in an increase in the number of LDL-receptors on cell surfaces and enhanced receptor-mediated catabolism and clearance of circulating LDL. Second, pravastatin inhibits LDL production by inhibiting hepatic synthesis of VLDL, the LDL precursor.
Related Articles
AbsorptionPravastatin is rapidly absorbed with peak plasma levels of the parent compound achieved 1 to 1.5 hours after administration. The average oral absorption of pravastatin is 34% and absolute bioavailability is 17%. These values however, are variable. Food decreases the systemic bioavailability but the lipid-lowering effect is not impacted. When 20 mg of pravastatin is given orally, the pharmacokinetic parameters are as follows: Cmax = 23.3-26.3 ng/mL; AUC = 54.7 to 62.2 ng•hr/mL.
Volume of distributionNot Available
Protein binding50% bound to human plasma proteins.
Metabolism

Hepatic, there is a small amount of metabolism by P450 enzymes, but this effect is so minimal that inhibitory pharmacokinetic drug interactions have no real effect on its overall activity and elimination. An in vitro study which found moderate affinity for P450 2C9 (major), 2D6 and 3A4. Furthermore, the major degradation product is the 3α-hydroxy isomeric metabolite, which has one-tenth to one-fortieth the HMG-CoA reductase inhibitory activity of the parent compound.

Route of eliminationApproximately 20% of a radiolabeled oral dose is excreted in urine and 70% in the feces. After intravenous administration, 47% of total body clearance was via renal excretion, while 53% was eliminated by non-renal routes.
Half life77 hours
ClearanceNot Available
ToxicitySide effects include diarrhea, nausea, constipation, gas abdominal pain, myopathy, myositis, rhabdomyolysis, and hepatotoxicity. LD50= 12,000 mg/kg (orally in rat)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Pravastatin Action PathwayDrug actionSMP00089
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Kinesin-like protein KIF6
Gene symbol: KIF6
UniProt: Q6ZMV9
rs20455 Not AvailableC AlleleImproved response to statin drugs18222353
3-hydroxy-3-methylglutaryl-coenzyme A reductase
Gene symbol: HMGCR
UniProt: P04035
rs17244841 Not AvailableT AlleleReduced response to statin drugs15199031
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Bristol myers squibb
  • Apotex corp
  • Dr reddys laboratories inc
  • Glenmark generics ltd
  • Lek pharmaceuticals dd
  • Lupin pharmaceuticals inc
  • Matrix laboratories ltd
  • Mylan pharmaceuticals inc
  • Pliva hrvatska doo
  • Ranbaxy laboratories ltd
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
Tablet (delayed-release); kit; tabletoral
Tabletoral20 mg/1
Tabletoral40 mg/1
Tabletoral80 mg/1
Tabletoral80 mg
Tabletoral10 mg
Tabletoral20 mg
Tabletoral40 mg
Tabletoral10 mg/1
Prices
Unit descriptionCostUnit
Pravachol 40 mg tablet6.53USD tablet
Pravachol 80 mg tablet6.53USD tablet
Pravastatin sodium 40 mg tablet4.89USD tablet
Pravastatin sodium 80 mg tablet4.89USD tablet
Pravachol 20 mg tablet4.39USD tablet
Pravachol 10 mg tablet4.38USD tablet
Pravastatin sodium 20 mg tablet3.33USD tablet
Pravastatin sodium 10 mg tablet3.28USD tablet
Apo-Pravastatin 40 mg Tablet1.42USD tablet
Co Pravastatin 40 mg Tablet1.42USD tablet
Jamp-Pravastatin 40 mg Tablet1.42USD tablet
Mint-Pravastatin 40 mg Tablet1.42USD tablet
Mylan-Pravastatin 40 mg Tablet1.42USD tablet
Novo-Pravastatin 40 mg Tablet1.42USD tablet
Pms-Pravastatin 40 mg Tablet1.42USD tablet
Pravachol 40 mg Tablet1.42USD tablet
Ran-Pravastatin 40 mg Tablet1.42USD tablet
Ratio-Pravastatin 40 mg Tablet1.42USD tablet
Sandoz Pravastatin 40 mg Tablet1.42USD tablet
Apo-Pravastatin 20 mg Tablet1.18USD tablet
Co Pravastatin 20 mg Tablet1.18USD tablet
Jamp-Pravastatin 20 mg Tablet1.18USD tablet
Mint-Pravastatin 20 mg Tablet1.18USD tablet
Mylan-Pravastatin 20 mg Tablet1.18USD tablet
Novo-Pravastatin 20 mg Tablet1.18USD tablet
Pms-Pravastatin 20 mg Tablet1.18USD tablet
Pravachol 20 mg Tablet1.18USD tablet
Ran-Pravastatin 20 mg Tablet1.18USD tablet
Ratio-Pravastatin 20 mg Tablet1.18USD tablet
Sandoz Pravastatin 20 mg Tablet1.18USD tablet
Apo-Pravastatin 10 mg Tablet1.0USD tablet
Co Pravastatin 10 mg Tablet1.0USD tablet
Jamp-Pravastatin 10 mg Tablet1.0USD tablet
Mint-Pravastatin 10 mg Tablet1.0USD tablet
Mylan-Pravastatin 10 mg Tablet1.0USD tablet
Novo-Pravastatin 10 mg Tablet1.0USD tablet
Pms-Pravastatin 10 mg Tablet1.0USD tablet
Pravachol 10 mg Tablet1.0USD tablet
Ran-Pravastatin 10 mg Tablet1.0USD tablet
Ratio-Pravastatin 10 mg Tablet1.0USD tablet
Sandoz Pravastatin 10 mg Tablet1.0USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1323836 No1993-11-022010-11-02Canada
US5622985 No1994-10-222014-10-22Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point171.2 - 173°CMSDS
water solubilitySoluble FDA label
logP0.59 FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.242 mg/mLALOGPS
logP2.23ALOGPS
logP1.65ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)4.21ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area124.29 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity113.6 m3·mol-1ChemAxon
Polarizability46.56 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Kae Jong Chung, Joo Kyung Lee, Joo Woong Park, Dong Jin Seo, Sang Choon Lee, “Method for producing pravastatin precursor, ML-236B.” U.S. Patent US6204032, issued October, 1976.

US6204032
General ReferencesNot Available
External Links
ATC CodesC10AA03C10BA03C10BX02
AHFS Codes
  • 24:06.08
PDB EntriesNot Available
FDA labelDownload (145 KB)
MSDSDownload (44 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolPravastatin may increase the anticoagulant activities of Acenocoumarol.
AcipimoxAcipimox may increase the myopathic rhabdomyolysis activities of Pravastatin.
Aluminum hydroxideThe serum concentration of Pravastatin can be decreased when it is combined with Aluminum hydroxide.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Pravastatin.
BezafibrateBezafibrate may increase the myopathic rhabdomyolysis activities of Pravastatin.
BoceprevirThe serum concentration of Pravastatin can be increased when it is combined with Boceprevir.
Calcium carbonateThe serum concentration of Pravastatin can be decreased when it is combined with Calcium carbonate.
CholestyramineThe serum concentration of Pravastatin can be decreased when it is combined with Cholestyramine.
CiprofibrateThe risk or severity of adverse effects can be increased when Ciprofibrate is combined with Pravastatin.
ClarithromycinThe serum concentration of Pravastatin can be increased when it is combined with Clarithromycin.
ColchicineColchicine may increase the myopathic rhabdomyolysis activities of Pravastatin.
ColesevelamThe serum concentration of Pravastatin can be decreased when it is combined with Colesevelam.
ColestipolThe serum concentration of Pravastatin can be decreased when it is combined with Colestipol.
CyclosporineThe serum concentration of Pravastatin can be increased when it is combined with Cyclosporine.
DaclatasvirThe serum concentration of Pravastatin can be increased when it is combined with Daclatasvir.
DaptomycinThe risk or severity of adverse effects can be increased when Pravastatin is combined with Daptomycin.
DarunavirThe serum concentration of Pravastatin can be increased when it is combined with Darunavir.
DicoumarolPravastatin may increase the anticoagulant activities of Dicoumarol.
EfavirenzThe serum concentration of Pravastatin can be decreased when it is combined with Efavirenz.
EltrombopagThe serum concentration of Pravastatin can be increased when it is combined with Eltrombopag.
ErythromycinThe serum concentration of Pravastatin can be increased when it is combined with Erythromycin.
FenofibrateThe risk or severity of adverse effects can be increased when Fenofibrate is combined with Pravastatin.
FosphenytoinThe serum concentration of Pravastatin can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe risk or severity of adverse effects can be increased when Fusidic Acid is combined with Pravastatin.
GemfibrozilGemfibrozil may increase the myopathic rhabdomyolysis activities of Pravastatin.
ItraconazoleThe serum concentration of Pravastatin can be increased when it is combined with Itraconazole.
LanthanumThe serum concentration of Lanthanum can be decreased when it is combined with Pravastatin.
Lanthanum carbonateThe serum concentration of Lanthanum carbonate can be decreased when it is combined with Pravastatin.
Magnesium hydroxideThe serum concentration of Pravastatin can be decreased when it is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Pravastatin can be decreased when it is combined with Magnesium oxide.
NelfinavirThe serum concentration of Pravastatin can be decreased when it is combined with Nelfinavir.
NiacinThe risk or severity of adverse effects can be increased when Niacin is combined with Pravastatin.
NicotinamideThe risk or severity of adverse effects can be increased when Nicotinamide is combined with Pravastatin.
ParoxetineThe risk or severity of adverse effects can be increased when Pravastatin is combined with Paroxetine.
PazopanibPravastatin may increase the hepatotoxic activities of Pazopanib.
PhenytoinThe serum concentration of Pravastatin can be decreased when it is combined with Phenytoin.
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Pravastatin.
RifabutinThe serum concentration of Pravastatin can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Pravastatin can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Pravastatin can be decreased when it is combined with Rifapentine.
SaquinavirThe serum concentration of Pravastatin can be decreased when it is combined with Saquinavir.
SimeprevirThe serum concentration of Pravastatin can be increased when it is combined with Simeprevir.
Sodium bicarbonateThe serum concentration of Pravastatin can be decreased when it is combined with Sodium bicarbonate.
TelaprevirThe serum concentration of Pravastatin can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Pravastatin can be increased when it is combined with Telithromycin.
TeriflunomideThe serum concentration of Pravastatin can be increased when it is combined with Teriflunomide.
TrabectedinPravastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.
WarfarinPravastatin may increase the anticoagulant activities of Warfarin.
Food Interactions
  • Avoid alcohol.
  • Avoid drastic changes in dietary habit.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Nadph binding
Specific Function:
Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including ubiquinone and geranylgeranyl proteins.
Gene Name:
HMGCR
Uniprot ID:
P04035
Molecular Weight:
97475.155 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150 ]
  2. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278 ]
  3. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800 ]
  4. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22. [PubMed:15970799 ]
  5. Sharma P, Holmes VE, Elsby R, Lambert C, Surry D: Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. Xenobiotica. 2010 Jan;40(1):24-37. doi: 10.3109/00498250903351013. [PubMed:19919292 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:
SLCO2B1
Uniprot ID:
O94956
Molecular Weight:
76709.98 Da
References
  1. Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ: Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics. 2009 Feb;19(2):129-38. doi: 10.1097/FPC.0b013e32831bd98c. [PubMed:19151602 ]
  2. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003 Aug;306(2):703-8. Epub 2003 Apr 30. [PubMed:12724351 ]
  3. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45. Epub 2003 Nov 10. [PubMed:14610227 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150 ]
  2. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359 ]
  2. Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, Sugiyama Y: Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther. 2002 Mar;300(3):746-53. [PubMed:11861777 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359 ]
  2. Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099 ]
  3. Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, Sugiyama Y: Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther. 2002 Mar;300(3):746-53. [PubMed:11861777 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150 ]
  2. Yamazaki M, Akiyama S, Ni'inuma K, Nishigaki R, Sugiyama Y: Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos. 1997 Oct;25(10):1123-9. [PubMed:9321514 ]
  3. Sasaki M, Suzuki H, Ito K, Abe T, Sugiyama Y: Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J Biol Chem. 2002 Feb 22;277(8):6497-503. Epub 2001 Dec 17. [PubMed:11748225 ]
  4. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9. Epub 2003 Apr 7. [PubMed:12682043 ]
  2. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Symporter activity
Specific Function:
Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. Depending on the tissue and on cicumstances, mediates the import or export of lactic acid and ketone bod...
Gene Name:
SLC16A1
Uniprot ID:
P53985
Molecular Weight:
53943.685 Da
References
  1. Tamai I, Takanaga H, Maeda H, Ogihara T, Yoneda M, Tsuji A: Proton-cotransport of pravastatin across intestinal brush-border membrane. Pharm Res. 1995 Nov;12(11):1727-32. [PubMed:8592677 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Morisawa Y, Takikawa H: Effect of bile acids on the biliary excretion of pravastatin in rats. Hepatol Res. 2009 Jun;39(6):595-600. doi: 10.1111/j.1872-034X.2009.00493.x. Epub 2009 Feb 24. [PubMed:19260999 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Link [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:08